RRx-001 is an investigational small molecule inflammasome NLRP3 inhibitor and Nrf2 upregulator with antioxidant and anti-inflammatory properties.
Narcan Nasal Spray for OTC use is expected to be available by late summer and will have the same formulation, device design, and 4mg strength as the prescription product.
Osemitamab is a high affinity, humanized antibody-dependent cellular cytotoxicity (ADCC)-enhanced anti-Claudin18.2 monoclonal antibody.
Lumateperone 42mg given once daily met the primary endpoint in the study.
The Lucira COVID-19 & Flu Home Test is available at a price of $34.99.
Zagociguat is a CNS-penetrant sGC stimulator.
The letter states that the application cannot be approved in its present form.
Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.
Joenja is supplied as 70mg tablets in 60-count bottles; it is expected to be available in early April 2023.
Results showed that 20.3% of patients treated with risankizumab achieved clinical remission at week 12 compared with 6.2% of patients who received placebo.
